Arecor Therapeutics
Biopharmaceutical company using its proprietary Arestat technology platform to develop superior biopharmaceutical products, with a focus on diabetes and specialty hospital products.
Notes
Arecor Therapeutics is a UK-based biopharmaceutical company that uses its proprietary Arestat technology platform to develop enhanced, differentiated versions of existing therapeutic proteins and peptides. The company's technology enables the development of products with improved stability, formulation characteristics, and device compatibility.
Arecor's lead programs focus on diabetes, including ultra-rapid-acting insulin formulations for insulin pump use and other diabetes management applications. The Arestat platform has demonstrated the ability to improve the stability and delivery characteristics of a wide range of therapeutic proteins.
The company is listed on the AIM market of the London Stock Exchange. Arecor partners with pharmaceutical companies to apply its formulation technology to their therapeutic products.
Team
- Sarah Howell - Chief Executive Officer
- LinkedIn: linkedin.com/in/sarah-howell
- Rachel Spence - Chief Financial Officer
- Marcus Sherlock - Chief Development Officer
Additional Research Findings
- Listed on AIM London Stock Exchange
- Proprietary Arestat technology platform
- Focus on insulin and diabetes products
- Ultra-rapid-acting insulin formulations for insulin pumps
- Cambridge, UK headquarters
- Partnerships with pharmaceutical companies
- Founded 2007
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| AlbionVC (Healthcare) | London, UK | biotech-focused | seedseries-a+1 | 17 |